Compare Stocks: PYXS, GUTS, PHAR, and IMMX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GUTS Fractyl Health	$4.42 +4.5%	$7.35	$4.14 ▼ $29.34	$58.61M	2.42	180,418 shs	197,876 shs
IMMX Immix Biopharma	$9.46 +1.8%	$11.83	$2.31 ▼ $15.10	$676.76M	0.24	1.79 million shs	1.11 million shs
PHAR Pharming Group	$9.79 +2.7%	$10.95	$9.44 ▼ $21.34	$692.92M	-0.05	35,452 shs	3,332 shs
PYXS Pyxis Oncology	$2.03 +2.0%	$3.10	$1.03 ▼ $5.55	$169.32M	1.37	1.27 million shs	950,365 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GUTS Fractyl Health	+4.49%	-9.41%	-42.45%	-53.53%	-73.69%
IMMX Immix Biopharma	+1.83%	-2.27%	-23.15%	-14.85%	+272.44%
PHAR Pharming Group	+2.73%	+0.41%	-10.76%	-29.37%	-33.69%
PYXS Pyxis Oncology	+2.01%	-5.14%	-39.94%	-23.97%	-30.24%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GUTS Fractyl Health	$4.42 +4.5%	$7.35	$4.14 ▼ $29.34	$58.61M	2.42	180,418 shs	197,876 shs
IMMX Immix Biopharma	$9.46 +1.8%	$11.83	$2.31 ▼ $15.10	$676.76M	0.24	1.79 million shs	1.11 million shs
PHAR Pharming Group	$9.79 +2.7%	$10.95	$9.44 ▼ $21.34	$692.92M	-0.05	35,452 shs	3,332 shs
PYXS Pyxis Oncology	$2.03 +2.0%	$3.10	$1.03 ▼ $5.55	$169.32M	1.37	1.27 million shs	950,365 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GUTS Fractyl Health	+4.49%	-9.41%	-42.45%	-53.53%	-73.69%
IMMX Immix Biopharma	+1.83%	-2.27%	-23.15%	-14.85%	+272.44%
PHAR Pharming Group	+2.73%	+0.41%	-10.76%	-29.37%	-33.69%
PYXS Pyxis Oncology	+2.01%	-5.14%	-39.94%	-23.97%	-30.24%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GUTS Fractyl Health	2.40	Hold	$66.00	1,393.21% Upside
IMMX Immix Biopharma	2.78	Moderate Buy	$24.14	155.21% Upside
PHAR Pharming Group	2.20	Hold	$38.67	294.96% Upside
PYXS Pyxis Oncology	2.70	Moderate Buy	$8.75	331.03% Upside

Current Analyst Ratings Breakdown

Latest PYXS, GUTS, PHAR, and IMMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	IMMX Immix Biopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/29/2026	IMMX Immix Biopharma	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$21.00 ➝ $30.00
9/25/2026	PYXS Pyxis Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/23/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$38.00
9/22/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/15/2026	IMMX Immix Biopharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$15.00 ➝ $26.00
9/14/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/10/2026	PYXS Pyxis Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$6.00 ➝ $8.00
9/10/2026	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $8.00
9/9/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$12.00 ➝ $19.00
9/3/2026	GUTS Fractyl Health	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GUTS Fractyl Health	$90K	651.21	N/A	N/A	$0.83 per share	5.33
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	$1.77 per share	N/A
PHAR Pharming Group	$376.13M	1.84	$0.20 per share	48.82	$3.95 per share	2.48
PYXS Pyxis Oncology	$13.86M	12.22	N/A	N/A	$0.86 per share	2.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GUTS Fractyl Health	-$140.95M	-$0.88	N/A	N/A	N/A	N/A	-1,362.10%	-84.89%	11/11/2026 (Estimated)
IMMX Immix Biopharma	-$29.44M	-$0.88	N/A	N/A	N/A	N/A	-38.44%	-34.72%	11/6/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	81.58	36.26	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)
PYXS Pyxis Oncology	-$79.62M	-$1.41	N/A	N/A	N/A	N/A	-215.23%	-112.19%	11/2/2026 (Estimated)

Latest PYXS, GUTS, PHAR, and IMMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	IMMX Immix Biopharma	-$0.19	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	PHAR Pharming Group	$0.12	N/A	N/A	N/A	$103.54 million	N/A
11/2/2026	Q3 2026	PYXS Pyxis Oncology	-$0.27	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	PYXS Pyxis Oncology	-$0.35	-$0.40	-$0.05	-$0.40	$0.03 million	N/A
8/10/2026	Q2 2026	GUTS Fractyl Health	-$1.62	-$1.44	+$0.18	-$0.16	N/A	N/A
8/7/2026	Q2 2026	IMMX Immix Biopharma	-$0.17	-$0.18	-$0.01	-$0.18	N/A	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GUTS Fractyl Health	N/A	N/A	N/A	N/A	N/A
IMMX Immix Biopharma	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GUTS Fractyl Health	1.41	3.15	3.15
IMMX Immix Biopharma	N/A	25.13	25.13
PHAR Pharming Group	0.34	3.01	2.31
PYXS Pyxis Oncology	N/A	1.34	1.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GUTS Fractyl Health	N/A
IMMX Immix Biopharma	11.26%
PHAR Pharming Group	0.03%
PYXS Pyxis Oncology	39.07%

Insider Ownership

Company	Insider Ownership
GUTS Fractyl Health	8.36%
IMMX Immix Biopharma	30.30%
PHAR Pharming Group	2.07%
PYXS Pyxis Oncology	5.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GUTS Fractyl Health	73	13.26 million	12.15 million	N/A
IMMX Immix Biopharma	21	71.54 million	49.86 million	Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable
PYXS Pyxis Oncology	56	83.41 million	78.65 million	Optionable

PYXS, GUTS, PHAR, and IMMX Headlines

Recent News About These Companies

Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D

October 4, 2026 | seekingalpha.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Has Average Target Price of $8.75

October 4, 2026 | americanbankingnews.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Analysts

October 4, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX) and Pyxis Oncology (PYXS)

October 3, 2026 | theglobeandmail.com

Pyxis Oncology Closes $110 Million Public Offering to Advance MICVO Clinical Development

October 2, 2026 | quiverquant.comQ

Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering

October 2, 2026 | globenewswire.com

Comparing Pyxis Oncology (NASDAQ:PYXS) & Inovio Pharmaceuticals (NASDAQ:INO)

October 1, 2026 | americanbankingnews.com

Pyxis Oncology prices public offering expected to raise ~$110 million

September 30, 2026 | thepharmaletter.comT

Pyxis Prices $110 Mln Offering, With Potential Proceeds Of $282 Mln To Advance Lead Cancer Drug

September 30, 2026 | rttnews.com

Biggest stock movers Wednesday: BA, PYXS, NOC, and more

September 30, 2026 | msn.com

Pyxis Oncology shares slide after pricing $110M registered public offering

September 30, 2026 | seekingalpha.com

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

September 30, 2026 | globenewswire.com

Pyxis Oncology Announces Proposed Public Offering - September 29, 2026

September 29, 2026 | biospace.comB

Pyxis Oncology terminates $150M ATM stock offering program

September 29, 2026 | streetinsider.com

Acciones de Pyxis Oncology caen tras anuncio de oferta pública

September 29, 2026 | es-us.finanzas.yahoo.com

Pyxis Oncology stock falls on public offering announcement

September 29, 2026 | finance.yahoo.com

Pyxis Oncology Announces Proposed Registered Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants

September 29, 2026 | quiverquant.comQ

Pyxis Oncology Announces Proposed Public Offering

September 29, 2026 | globenewswire.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

September 23, 2026 | theglobeandmail.com

Pyxis Oncology consensus price target increased by 16.92% to $8.61

September 15, 2026 | msn.com

HC Wainwright Raises Earnings Estimates for Pyxis Oncology

September 14, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PYXS, GUTS, PHAR, and IMMX Company Descriptions

Fractyl Health NASDAQ:GUTS

$4.42 +0.19 (+4.49%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.50 +0.08 (+1.81%)

As of 10/9/2026 07:51 PM Eastern

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Immix Biopharma NASDAQ:IMMX

$9.46 +0.17 (+1.83%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$9.45 -0.01 (-0.11%)

As of 10/9/2026 07:52 PM Eastern

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Pharming Group NASDAQ:PHAR

$9.79 +0.26 (+2.73%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$9.77 -0.02 (-0.20%)

As of 10/9/2026 07:30 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Pyxis Oncology NASDAQ:PYXS

$2.03 +0.04 (+2.01%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.03 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYXS, GUTS, PHAR, and IMMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYXS, GUTS, PHAR, and IMMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYXS, GUTS, PHAR, and IMMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PYXS, GUTS, PHAR, and IMMX Company Descriptions

Fractyl Health NASDAQ:GUTS

Immix Biopharma NASDAQ:IMMX

Pharming Group NASDAQ:PHAR

Pyxis Oncology NASDAQ:PYXS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYXS, GUTS, PHAR, and IMMX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYXS, GUTS, PHAR, and IMMX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYXS, GUTS, PHAR, and IMMX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PYXS, GUTS, PHAR, and IMMX Company Descriptions

Fractyl Health NASDAQ:GUTS

Immix Biopharma NASDAQ:IMMX

Pharming Group NASDAQ:PHAR

Pyxis Oncology NASDAQ:PYXS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools